Abstract Number: 2461 • 2019 ACR/ARP Annual Meeting
Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement
Background/Purpose: Oligoarticular disease in patients with psoriatic arthritis (PsA) is often underdiagnosed and undertreated. The goal of this study is to understand and identify current…Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting
The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort
Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…Abstract Number: 302 • 2019 ACR/ARP Annual Meeting
Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center
Background/Purpose: Routine use of musculoskeletal ultrasound (MSK-US) to aid in clinical decision-making for rheumatology patients is less common in the United States than in Europe,…Abstract Number: 654 • 2019 ACR/ARP Annual Meeting
Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease
Background/Purpose: Undifferentiated Connective Tissue Disease (UCTD) describes the clinical scenario where a patient demonstrates characteristics of a connective tissue disease but does not meet criteria…Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting
Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…Abstract Number: 2155 • 2018 ACR/ARHP Annual Meeting
Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease that is characterised by fibroblast dysfunction and excess extracellular matrix deposition that leads to skin thickening and…Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…Abstract Number: 2516 • 2018 ACR/ARHP Annual Meeting
Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
Background/Purpose: The safety and efficacy of certolizumab pegol (CZP) for treating patients (pts) with rheumatoid arthritis (RA) are well-established in a clinical trial setting.1,2 However,…Abstract Number: 2589 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Few real-world studies have characterized patients with psoriatic arthritis (PsA) who initiate secukinumab. This study described characteristics of patients who initiated secukinumab and other…Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
- 1
- 2
- 3
- …
- 8
- Next Page »